Cargando…
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma
Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventuall...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669790/ https://www.ncbi.nlm.nih.gov/pubmed/38002311 http://dx.doi.org/10.3390/biom13111629 |
_version_ | 1785139775346311168 |
---|---|
author | Sharma, Niyati Seshagiri Choudhary, Bibha |
author_facet | Sharma, Niyati Seshagiri Choudhary, Bibha |
author_sort | Sharma, Niyati Seshagiri |
collection | PubMed |
description | Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventually contribute to the development of drug resistance. The bone marrow microenvironment (BMME) is composed of a cellular component comprising stromal cells, endothelial cells, osteoclasts, osteoblasts, and immune cells, and a non-cellular component made of the extracellular matrix (ECM) and the liquid milieu, which contains cytokines, growth factors, and chemokines. The bone marrow stromal cells (BMSCs) are involved in the adhesion of MM cells, promote the growth, proliferation, invasion, and drug resistance of MM cells, and are also crucial in angiogenesis and the formation of lytic bone lesions. Classical immunophenotyping in combination with advanced immune profiling using single-cell sequencing technologies has enabled immune cell-specific gene expression analysis in MM to further elucidate the roles of specific immune cell fractions from peripheral blood and bone marrow (BM) in myelomagenesis and progression, immune evasion and exhaustion mechanisms, and development of drug resistance and relapse. The review describes the role of BMME components in MM development and ongoing clinical trials using immunotherapeutic approaches. |
format | Online Article Text |
id | pubmed-10669790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106697902023-11-07 Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma Sharma, Niyati Seshagiri Choudhary, Bibha Biomolecules Review Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventually contribute to the development of drug resistance. The bone marrow microenvironment (BMME) is composed of a cellular component comprising stromal cells, endothelial cells, osteoclasts, osteoblasts, and immune cells, and a non-cellular component made of the extracellular matrix (ECM) and the liquid milieu, which contains cytokines, growth factors, and chemokines. The bone marrow stromal cells (BMSCs) are involved in the adhesion of MM cells, promote the growth, proliferation, invasion, and drug resistance of MM cells, and are also crucial in angiogenesis and the formation of lytic bone lesions. Classical immunophenotyping in combination with advanced immune profiling using single-cell sequencing technologies has enabled immune cell-specific gene expression analysis in MM to further elucidate the roles of specific immune cell fractions from peripheral blood and bone marrow (BM) in myelomagenesis and progression, immune evasion and exhaustion mechanisms, and development of drug resistance and relapse. The review describes the role of BMME components in MM development and ongoing clinical trials using immunotherapeutic approaches. MDPI 2023-11-07 /pmc/articles/PMC10669790/ /pubmed/38002311 http://dx.doi.org/10.3390/biom13111629 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Sharma, Niyati Seshagiri Choudhary, Bibha Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma |
title | Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma |
title_full | Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma |
title_fullStr | Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma |
title_full_unstemmed | Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma |
title_short | Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma |
title_sort | good cop, bad cop: profiling the immune landscape in multiple myeloma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10669790/ https://www.ncbi.nlm.nih.gov/pubmed/38002311 http://dx.doi.org/10.3390/biom13111629 |
work_keys_str_mv | AT sharmaniyatiseshagiri goodcopbadcopprofilingtheimmunelandscapeinmultiplemyeloma AT choudharybibha goodcopbadcopprofilingtheimmunelandscapeinmultiplemyeloma |